Lung cancer liver metastases are tumors that form in the liver from cancer cells that have broken away from the primary cancer and spread through the blood or lymphatic system. The liver is a common ...

Sometimes, lung cancer comes back after you’ve had treatment. This is called a recurrence. It can happen at any time or not at all. But lung cancer is most likely to return within 5 years after ...

Background Pulmonary hypertension (PHT) lacks community prevalence and outcome data. Objective To characterise minimum ‘indicative’ prevalences and mortality data for all forms of PHT in a selected ...

Background Recent evidence showed that 50% of chronic obstructive pulmonary disease (COPD) may be attributable to air pollution. We aimed to investigate the association between long-term air pollution ...

1Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli, Taiwan. 2Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.

Hamartomas, about whose etiology little is known, show a uniform distribution throughout the middle decades. With asymptomatic pulmonary lesions it is universally recognized that few diagnostic ...

Common anticancer drugs may offer new hope to PTEN Hamartoma Tumour Syndrome patients. ScienceDaily . Retrieved April 17, 2025 from www.sciencedaily.com / releases / 2025 / 03 / 250331122120.htm ...

A rapid test harnessing the power of AI is set to transform the diagnosis of a lung condition that affects 3 million people in the UK. Two thirds of those with chronic obstructive pulmonary ...

The device, known as N-Tidal Diagnose, uses carbon dioxide sensors to measure changes in a patient’s lung function with results given in minutes. Dr Simon Rudland, a GP in Suffolk, showing the N ...

The story of how Gerald McRaney was diagnosed with lung cancer is one of pure chance, but he's using his story as an opportunity to remind others not to skip their routine physicals or other doctor ...

If it lands in the lungs, it’s called a pulmonary embolism. Estimates vary widely, but according to the American Lung Association, around 900,000 U.S. adults experience this type of potentially ...

BioN­Tech has high­ly en­cour­ag­ing sur­vival da­ta for its bis­pe­cif­ic an­ti­body com­bin­ing check­point block­ade with VEGF-A in­hi­bi­tion as a first-line treat­ment for ...